Monument Therapeutics secures £2.6m in seed funding led by Catapult Ventures to advance neuroscience drug development.
Catapult Ventures led the seed round alongside Neo Kuma Ventures, Wren Capital, and o2H ventures to support the Cambridge Cognition spinout.
Share allotment filed at Companies House
Monument Therapeutics is a stratified medicine company applying digital biomarkers to neuroscience drug development. The firm focuses on matching patient sub-groups with targeted compounds.
Monument Therapeutics has raised £2.6m in seed financing to spin out from Cambridge Cognition and establish operations in Cheshire. The funding round was spearheaded by Catapult Ventures alongside Neo Kuma Ventures, Wren Capital, and o2H ventures. The capital will support the company as it advances its therapeutic pipeline addressing cognitive impairment in schizophrenia and post-operative cognitive dysfunction.
The business repurposes compounds with proven safety profiles and combines them with proprietary cognitive stratification tools. This approach aims to reduce development risks while addressing significant unmet clinical needs across neurology and psychiatry.
Investors
Categories
About the company
Monument Therapeutics
Monument Therapeutics develops stratified treatments for central nervous system conditions using digital brain biomarkers.